Q3 2022 Results
Company overview
Financial performance
Cardiovascular
Financial review
2022 priorities
Appendix
Innovation: Pipeline overview
Innovation: Clinical trials
Immunology
Neuroscience
Oncology
LNA043 - ANGPTL3 agonist
NCT04864392 ONWARDS (CLNA043A12202)
Knee osteoarthritis
Phase 2
Indication
Phase
Patients
550
Primary
Outcome
Measures
Arms
Intervention
Target
Patients
Change from baseline in the cartilage thickness of the medial compartment of
the knee as assessed by imaging
LNA043 injection to the knee with dosing regimen A
LNA043 injection to the knee with dosing regimen B
LNA043 injection to the knee with dosing regimen C
LNA043 injection to the knee with dosing regimen D
Placebo injection to the knee
Patients with Symptomatic knee osteoarthritis
Primary 2024
Read-out
Milestone(s)
Publication
TBD
References
Abbreviations
Other
57 Investor Relations | Q3 2022 Results
NOVARTIS | Reimagining MedicineView entire presentation